96 reports

  • CHAPTER IV ARTHRITIS TREATMENT DRUGS PRODUCTION AND DEMAND
  • Arthritis Treatment Drugs Sales Volume

THEY ARE SAARDS(SLOW ACTING ANTI-RHEUMATIC DRUGS), TRADTIONAL CHINESE MEDICINE, BIOLOGICAL AGENTS AND ANTIBIOTICS.

  • Musculoskeletal Disorder
  • China
  • Demand
  • Trade
  • Ltd Sichuan Xichangyangtian Pharmaceutical Co.

Rheumatoid Arthritis Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026 ##.

  • Arthritis
  • Musculoskeletal Disorder
  • APAC
  • World
  • Company Financials
  • IV. ARTHRITIS TREATMENT DRUGS PRODUCTION AND
  • CHAPTER IV ARTHRITIS TREATMENT DRUGS PRODUCTION AND DEMAND

THEY ARE SAARDS(SLOW ACTING ANTI-RHEUMATIC DRUGS), TRADTIONAL CHINESE MEDICINE, BIOLOGICAL AGENTS AND ANTIBIOTICS.

  • Musculoskeletal Disorder
  • China
  • Demand
  • Bayer AG
  • Yunnan Baiyao Group Co., Ltd.
  • Cardiovascular Diseases

one of the world' s leading providers of company operational data and strategic analysis, providing detailed information on tens of thousands of companies globally.

  • Analgesic
  • Biomarker
  • Immunodiagnostics
  • Musculoskeletal Disorder
  • Firalis SAS

Global Market Study on Rheumatoid Arthritis Treatment: Trends Indicate the Prevalence of New Combination Treatment and Dual Inhibitors ##.

  • Arthritis
  • Musculoskeletal Disorder
  • APAC
  • World
  • Market Size

Product type include disease modifying anti-rheumatic drugs, non-steroidal anti-inflammatory drugs and corticosteroids.

  • Arthritis
  • Chronic Disease
  • Musculoskeletal Disorder
  • World
  • Market Size
  • 6.2 RHEUMATOID ARTHRITIS

Glucagon-like peptide-##, commonly known as GLP-##, is a hormone produced by the proglucagon gene in the L-cells of the gut.

  • Diabetes
  • Injectable Delivery
  • Musculoskeletal Disorder
  • North America
  • Amgen Inc.
  • GLOBAL MARKETS DIRECT REPORT COVERAGE

Treatment includes painkillers, NSAID and disease-modifying anti-rheumatic drugs.

  • Biosimilar
  • Musculoskeletal Disorder
  • United States
  • Company Operations
  • Product Initiative
  • SEP 08, 2017: NICE ISSUES POSITIVE RECOMMENDATION FOR XELJANZ (TOFACITINIB CITRATE) AS A NEW TREATMENT OPTION FOR ADULTS WITH SEVERE RHEUMATOID ARTHRITIS

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying anti-rheumatic drug (DMARD), such as methotrexate.

  • Musculoskeletal Disorder
  • Therapy
  • United States
  • Product Initiative
  • Pfizer Inc.

The guidance does not recommend abatacept in combination with methotrexate, for treating rheumatoid arthritis in adults whose disease has responded inadequately to one or more conventional non-biological disease modifying anti-rheumatic drugs (DMARDs) including methotrexate.

  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Galapagos NV
  • 5.2 MARKET DYNAMICS

Both cyclooxygenase (COX)-## selective NSAIDs (coxibs) and non-selective NSAIDs increase the risk of cardiovascular disease in patients.

  • Musculoskeletal Disorder
  • North America
  • United States
  • Market Size
  • Pfizer Inc.

The guidance does not recommend abatacept in combination with Regulatory Details Other Developmental Activities ##-Nov-2017 methotrexate, for treating rheumatoid arthritis in adults whose disease has responded inadequately to one or more conventional non-biological disease modifying

  • Autoimmune Disease
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Type 2 Diabetes
  • ChemoCentryx, Inc.

Competitive Landscape ##. ## Abbvie ##. ## Biogen Idec ##. ## Bristol-Myers Squibb ##. ## Celgene ##. ## Celltrion ##. ## J& J ##. ## MedImmune ##. ## Merck ##. ## Novartis ##. ## Takeda List of Figures Figure ##-##: Representation of the Disease Progression in Rheumatoid Arthritis Figure ##-

  • Anti Rheumatic
  • Arthritis
  • Musculoskeletal Disorder
  • Therapy
  • World
  • and safety of the IV formulation of ORENCIA in patients with lupus nephritis.
  • ABATACEPT - DRUG PROFILE

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug (DMARD), such as methotrexate.

  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • Neurological Disorder
  • United States
  • Pfizer Inc.
  • abatacept - Drug Profile

The molecules developed by Companies in Phase III, Phase II and Phase I stages are ##, ## and ## respectively.

  • Autoimmune Disease
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy
  • United States

Kevzara®(sarilumab) Injection In May 2017, the FDA approved Kevzara for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have an inadequate response or intolerance to one or more disease modifying anti-rheumatic drugs (DMARDs).

  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy
  • Regeneron Pharmaceuticals, Inc.

The prominent features of this report are - ##.

  • Musculoskeletal Disorder
  • Therapy
  • World
  • Product Initiative
  • UCB S.A.

RG## specifically targets TAMs by binding to colony-stimulating factor-## receptor (CSF-##R) on the cell surface and blocking its activation by CSF-##.

  • Musculoskeletal Disorder
  • Therapy
  • United States
  • Product Initiative
  • Plexxikon Inc.
  • Clinical Trial profile. 18 Trial Title

The PALACE trials evaluated the efficacy and safety of OTEZLA® twice daily (BID) versus placebo in adult subjects with active psoriatic arthritis despite prior conventional disease-modifying anti-rheumatic drugs and/ or biologics.

  • Autoimmune Disease
  • Musculoskeletal Disorder
  • Targeted Therapy
  • World
  • Product Initiative
  • and safety of the IV formulation of ORENCIA in patients with lupus nephritis.
  • ABATACEPT - DRUG PROFILE

Efficacy was maintained at ## year.

  • Musculoskeletal Disorder
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

The initial treatment option is disease-modifying antirheumatic drugs, also known as DMARDs.

  • Anti Rheumatic
  • Medical Biotechnology
  • Musculoskeletal Disorder
  • Therapy
  • United States
  • be assessed in this study.
  • U.S. National Institutes of Health.

Xeljanz may be used in patients in whom clinical symptoms due to the disease remain even after appropriate treatment with at least one other disease-modifying antirheumatic drug (DMARD), such as methotrexate.

  • Autoimmune Disease
  • Musculoskeletal Disorder
  • Therapy
  • United States
  • Product Initiative

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Clinical Trial
  • Musculoskeletal Disorder
  • Therapy
  • Pfizer Inc.
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The Impact of Antirheumatic Treatment on Antibody Response and Protection of Infections (Vaccimil) Vaccination in Inflammatory Rheumatic Disease (VACCIMIL).

  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • Pain Relief
  • World
  • Product Initiative

Celgene Corporation P A G E | ## P A G E | ## P A G E | ## Antirheumatic drugs are used in the treatment of rheumatoid arthritis to slow down the progression of disease.

  • Musculoskeletal Disorder
  • Company Financials
  • Forecast
  • GlaxoSmithKline plc
  • Pfizer Inc.

The molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Discovery stages are ##, ##, ## and ## respectively.

  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • United States
  • Product Initiative
  • Novartis AG
  • MAR 13, 2017: BRISTOL-MYERS SQUIBB'S ORENCIA REJECTS FOR USE WITHIN NHS SCOTLAND

CST. ## RA.

  • Arthritis
  • Immunotherapy
  • Musculoskeletal Disorder
  • Therapy
  • Bristol-Myers Squibb Company
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Medical Biotechnology
  • Musculoskeletal Disorder
  • Neurological Disorder
  • World
  • Product Initiative

In Part ##, eight healthy volunteers per dose cohort were randomized (##:##) to receive a single intravenous infusion of FPA## (at dose levels of ##. ##, ##, ##, or ## mg/ kg) or placebo.

  • Musculoskeletal Disorder
  • Therapy
  • United States
  • Product Initiative
  • Plexxikon Inc.

The company provides drugs such as psychoneurotic, anti-cancer, cardiovascular, antihistamine, antirheumatic and benign prostatic hyperplasia drugs, among others.

  • Clinical Trial
  • Musculoskeletal Disorder
  • United States
  • Company
  • Anika Therapeutics, Inc.